Dna Biomed Solns Stock Current Valuation
| DNA Stock | ILS 88.80 6.50 6.82% |
Valuation analysis of DNA Biomed Solns helps investors to measure DNA Biomed's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that DNA Biomed's price fluctuation is very steady at this time. Calculation of the real value of DNA Biomed Solns is based on 3 months time horizon. Increasing DNA Biomed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for DNA Biomed Solns is useful when determining the fair value of the DNA stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of DNA Biomed. Since DNA Biomed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DNA Stock. However, DNA Biomed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 88.8 | Real 73.29 | Hype 89.6 |
The real value of DNA Stock, also known as its intrinsic value, is the underlying worth of DNA Biomed Solns Company, which is reflected in its stock price. It is based on DNA Biomed's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of DNA Biomed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence DNA Biomed's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of DNA Biomed Solns helps investors to forecast how DNA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DNA Biomed more accurately as focusing exclusively on DNA Biomed's fundamentals will not take into account other important factors: DNA Biomed Solns Company Current Valuation Analysis
DNA Biomed's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current DNA Biomed Current Valuation | 59.57 M |
Most of DNA Biomed's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNA Biomed Solns is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, DNA Biomed Solns has a Current Valuation of 59.57 M. This is 99.59% lower than that of the Electronic Equipment, Instruments & Components sector and 98.72% lower than that of the Information Technology industry. The current valuation for all Israel stocks is 99.64% higher than that of the company.
DNA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNA Biomed's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNA Biomed could also be used in its relative valuation, which is a method of valuing DNA Biomed by comparing valuation metrics of similar companies.DNA Biomed is currently under evaluation in current valuation category among related companies.
DNA Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Shares Owned By Insiders | 54.87 % | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Net Income | 18.37 M | |||
| Cash And Equivalents | 492 K | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (2.33 M) | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 11 | |||
| Beta | 0.31 | |||
| Market Capitalization | 86.46 M | |||
| Total Asset | 54.62 M | |||
| Retained Earnings | (139 M) | |||
| Working Capital | 18 M | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
| Z Score | -2.8 | |||
| Net Asset | 54.62 M |
About DNA Biomed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNA Biomed Solns's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNA Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNA Biomed Solns based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with DNA Biomed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DNA Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DNA Biomed will appreciate offsetting losses from the drop in the long position's value.Moving together with DNA Stock
| 0.64 | DCI | Direct Capital Inves | PairCorr |
| 0.78 | SAFE | Safe T Group | PairCorr |
Moving against DNA Stock
| 0.77 | FVT | Ai Conversation Systems | PairCorr |
| 0.69 | GIVO-L | GIVOT OLAM OIL | PairCorr |
The ability to find closely correlated positions to DNA Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DNA Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DNA Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DNA Biomed Solns to buy it.
The correlation of DNA Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DNA Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DNA Biomed Solns moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DNA Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNA Biomed Solns. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |